Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study

被引:34
|
作者
Verhagen, Sandra N. [1 ]
Wassink, Annemarie M. J. [1 ]
van der Graaf, Yolanda [2 ]
Gorter, Petra M. [1 ]
Visseren, Frank L. J. [1 ]
机构
[1] Univ Med Ctr Utrecht UMC Utrecht, Dept Vasc Med, Utrecht, Netherlands
[2] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源
关键词
Insulin resistance; Manifest arterial disease; Metabolic syndrome; HOMEOSTASIS MODEL ASSESSMENT; ABDOMINAL AORTIC-ANEURYSM; GLUCOSE CLAMP TECHNIQUE; CORONARY-HEART-DISEASE; METABOLIC SYNDROME; CEREBROVASCULAR-DISEASE; INCREASED RISK; SENSITIVITY; STIFFNESS; OBESITY;
D O I
10.1186/1475-2840-10-100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Insulin resistance is accompanied by a cluster of metabolic changes, often referred to as metabolic syndrome. Metabolic syndrome is associated with an increased cardiovascular risk in patients with manifest arterial disease. We investigated whether insulin resistance is associated with an increased risk for cardiovascular events in patients with manifest arterial disease without known diabetes and whether this can be explained by the components of the metabolic syndrome or by inflammation. Methods: Prospective cohort study in 2611 patients with manifest arterial disease without known diabetes. Homeostasis model of insulin resistance (HOMA-IR) was used to quantify insulin resistance. The relation of HOMA-IR with cardiovascular events (vascular death, myocardial infarction or stroke) and all cause mortality was assessed with Cox regression analysis. In additional models adjustments were performed for the single components constituting the metabolic syndrome and for inflammation. Results: HOMA-IR increases with the number of metabolic syndrome components (mean HOMA-IR +/- SD in groups with 0, 1, 2, 3, 4 and 5 metabolic syndrome components: 1.4 +/- 0.7; 1.8 +/- 1.2; 2.4 +/- 1.5; 3.1 +/- 1.8; 4.0 +/- 2.6; and 5.6 +/- 3.6 respectively). High HOMA-IR was independently associated with an increased risk of cardiovascular events (tertile 2 vs. 1 HR 1.92; 95% CI 1.20-3.08) (tertile 3 vs. 1 HR 1.78; 95% CI 1.10-2.89) and with all cause mortality (tertile 2 vs. 1 HR 1.80; 95% CI 1.04-3.10) (tertile 3 vs. 1 HR 1.56; 95% CI 0.88-2.75). These relations were not influenced by the individual components of metabolic syndrome or by inflammation. Conclusions: In patients with manifest arterial disease without known diabetes, insulin resistance increases with the number of metabolic syndrome components, and elevated insulin resistance increases the risk of new cardiovascular events.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study
    Dijk, Joke M.
    van der Graaf, Yolanda
    Bots, Michiel L.
    Grobbee, Diederick E.
    Algra, Ale
    EUROPEAN HEART JOURNAL, 2006, 27 (16) : 1971 - 1978
  • [22] Correspondence: insulin resistance and chronic kidney disease in patients without diabetes
    Hong Tham Pham
    Kim-Huong Truong-Nguyen
    Minh-Hoang Tran
    BMC Nephrology, 26 (1)
  • [23] Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Tonkin, Andrew
    Hunt, David
    Voysey, Merryn
    Kesaniemi, Antero
    Hamer, Andrew
    Waites, Jonathon
    Mahar, Leo
    Mann, Stewart
    Glasziou, Paul
    Forder, Peta
    Simes, John
    Keech, Anthony C.
    AMERICAN HEART JOURNAL, 2012, 163 (03) : 508 - 514
  • [24] Effect of amlodipine and enalapril on cardiovascular events in patients with insulin resistance and diabetes in the CAMELOT trial
    Baghdasarian, SB
    Thompson, PD
    Shi, H
    Thakker, KM
    Tuzcu, ME
    Nissen, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 309A - 309A
  • [25] Arterial compliance and insulin resistance in hypertensive patients with and without diabetes mellitus type II
    Oren, S
    Golzman, B
    Kogan, J
    Turkot, S
    Isakov, I
    Peled, R
    JOURNAL OF HYPERTENSION, 2005, 23 : S36 - S36
  • [26] Serial measurement of B-type natriuretic peptide and future cardiovascular events in patients with type 2 diabetes mellitus without known cardiovascular disease
    Ikeda, Shota
    Shinohara, Keisuke
    Enzan, Nobuyuki
    Matsushima, Shouji
    Tohyama, Takeshi
    Funakoshi, Kouta
    Kishimoto, Junji
    Itoh, Hiroshi
    Komuro, Issei
    Tsutsui, Hiroyuki
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 356 : 98 - 104
  • [27] Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
    Cruickshank, JM
    LANCET, 2002, 359 (9324): : 2200 - 2201
  • [28] Prevalence of and risk factors for peripheral arterial disease among Chinese hypertensive patients with and without known cardiovascular disease
    Zheng, Liqiang
    Yu, Jinming
    Li, Jue
    Li, Xiankai
    Luo, Yingyi
    Hasimu, Buaijiaer
    Sun, Zhaoqing
    Sun, Yingxian
    Hu, Dayi
    ACTA CARDIOLOGICA, 2008, 63 (06) : 693 - 699
  • [29] Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: Data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study
    Sprengers, Ralf W.
    Janssen, Kristel J. M.
    Moll, Frans L.
    Verhaar, Marianne C.
    van der Graaf, Yolanda
    JOURNAL OF VASCULAR SURGERY, 2009, 50 (06) : 1369 - 1377
  • [30] Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: The mild and moderate kidney disease study
    Becker, B
    Kronenberg, F
    Kielstein, JT
    Haller, H
    Morath, C
    Ritz, E
    Fliser, D
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04): : 1091 - 1098